Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor

Name: Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor
Published: 2011
License: Public Domain

AbbVie (prior sponsor, Abbott) · 2011

ClinicalTrials.gov · Datasets · License: Public Domain · 2011

Open Source ↗

chronic-kidney-disease diabetic-nephropathy

chronic kidney disease, diabetic nephropathy, endothelin receptor antagonists, proteinuria, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor

Related documents